RTP-based Norak Biosciences, Inc. (www.norakbio.com) has signed a second license agreement with AstraZeneca to continue use of Transfluor Technology in its G protein-coupled receptor (GPCR) drug discovery program. Financial terms were not disclosed.
AstraZeneca will use Transfluor to advance novel lead compounds discovered from a primary high throughput screen utilizing Transfluor under an agreement announced in June 2002. The terms of the 2002 agreement called for Norak to develop a cell line for an AstraZeneca GPCR target of interest that was then screened by AstraZeneca, according to company reports. Norak's Transfluor technology is a patented, universal GPCR drug discovery technology designed to be the most direct and accurate method for screening potential drug candidates against GPCR targets, whether known or orphan.
Norak Biosciences is a CED member.